Labcorp Holdings Inc.’s Stock Price Soars to $240.42, Marking a Robust 4.71% Increase

Labcorp Holdings Inc. (LH)

240.42 USD +10.82 (+4.71%) Volume: 2.27M

Labcorp Holdings Inc.’s stock price is currently standing strong at 240.42 USD, marking an impressive trading session increase of +4.71%. With a robust trading volume of 2.27M and a year-to-date percentage jump of +4.84%, LH’s stock performance continues to show promising growth, making it a potential choice for savvy investors.

Latest developments on Labcorp Holdings Inc.

Laboratory Corporation of America Holdings, also known as Labcorp, saw a boost in its stock price today after beating quarterly profit estimates due to increased demand for diagnostic tests. The company’s first quarter earnings snapshot revealed strong performance, leading to positive investor sentiment. Additionally, Labcorp is facing a potential class action lawsuit in federal court, which has also impacted stock price movements. As a key player in the biomarker discovery outsourcing services market, Labcorp continues to attract attention from investors and analysts alike.

Labcorp Holdings Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma have been closely monitoring Laboratory Corporation of America Holdings (LabCorp). In their report titled “LH US – Labcorp Holdings: Is Its Stronghold in Diagnostics Under Threat?”, they highlighted a mixed but generally positive financial report from LabCorp. The company saw a 10% increase in revenue in 2024, with both their Diagnostics and Biopharma Laboratory Services segments showing commendable 10% growth. This report provides investors with signals to consider both an optimistic outlook and ongoing challenges.

Another report by Baptista Research on Smartkarma, titled “Laboratory Corporation of America Holdings (LabCorp): Advancement in Oncology Diagnostics & Other Major Highlights Of Q3 That Could Have A Long Term Impact! – Financial Forecasts”, discussed LabCorp’s financial results for the third quarter of 2024. Despite facing margin pressures, partially due to the integration of Invitae, LabCorp reported a 7% year-over-year revenue increase to $3.3 billion. Diagnostics Laboratories exhibited a 9% growth, while Biopharma Laboratory Services rose by approximately 3%. Analysts are keeping a close eye on these developments for potential long-term impacts on the company.

A look at Labcorp Holdings Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Laboratory Corporation of America Holdings has a positive long-term outlook. With high scores in Value, Momentum, and Resilience, the company is positioned well for future growth and stability. The company’s focus on providing clinical laboratory tests for routine testing, patient diagnosis, and disease monitoring, along with specialty testing operations, contributes to its overall strong performance.

Although Laboratory Corporation of America Holdings scored lower in Growth and Dividend, the company’s strong performance in other areas indicates a promising outlook. With a solid foundation in clinical laboratory services and a commitment to specialty testing operations, Laboratory Corporation of America Holdings is well-positioned to continue its success in the long term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma